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Aims Sodium-channel blockers (SCBs) are associated with arrhythmia, but variability of cardiac electrical response
remains unexplained. We sought to identify predictors of ajmaline-induced PR and QRS changes and Type I
Brugada syndrome (BrS) electrocardiogram (ECG).
...................................................................................................................................................................................................
Methods
and results
In 1368 patients that underwent ajmaline infusion for suspected BrS, we performed measurements of 26 721
ECGs, dose–response mixed modelling and genotyping. We calculated polygenic risk scores (PRS) for PR interval
(PRSPR), QRS duration (PRSQRS), and Brugada syndrome (PRSBrS) derived from published genome-wide association
studies and used regression analysis to identify predictors of ajmaline dose related PR change (slope) and QRS
slope. We derived and validated using bootstrapping a predictive model for ajmaline-induced Type I BrS ECG.
Higher PRSPR, baseline PR, and female sex are associated with more pronounced PR slope, while PRSQRS and age
are positively associated with QRS slope (P< 0.01 for all). PRSBrS, baseline QRS duration, presence of Type II or III
BrS ECG at baseline, and family history of BrS are independently associated with the occurrence of a Type I BrS
ECG, with good predictive accuracy (optimism-corrected C-statistic 0.74).
...................................................................................................................................................................................................
Conclusion We show for the first time that genetic factors underlie the variability of cardiac electrical response to SCB.
PRSBrS, family history, and a baseline ECG can predict the development of a diagnostic drug-induced Type I BrS
ECG with clinically relevant accuracy. These findings could lead to the use of PRS in the diagnosis of BrS and, if
confirmed in population studies, to identify patients at risk for toxicity when given SCB.
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Introduction
Cardiac arrhythmia as a consequence of the use of cardiac and non-
cardiac drugs is a long-recognized clinical problem, notably QT pro-
longation and torsades de pointes. Rare monogenic variants causing
drug-induced torsades de pointes are uncommon, and mostly reported
in patients with unrecognized congenital long QT syndrome.
Recently, a polygenic risk score derived from a QT interval study in
100 000 subjects1—i.e. based on common genetic variants that
modulate the QT in the general population—has been shown to pre-
dict drug-induced QT prolongation and torsades de pointes.2 These
findings support a vision of pre-prescription genotyping to reduce ad-
verse events.
Impaired cardiac depolarization predisposes to cardiac arrhyth-
mias, through conduction block and re-entry. Sodium-channel block-
ing drugs inhibiting cardiomyocyte depolarization are associated with
major adverse cardiovascular events, both in the general popula-
tion3–6 and in specific patient subgroups.7–9 These studies demon-
strate the potential for cardiac adverse events using sodium-channel
blockers (SCBs) prescribed both for cardiac arrhythmia7,8,10 as well
as for non-cardiac conditions.3–6 The presence of structural heart dis-
ease and myocardial ischaemia are well-recognized risk factors, yet,
SCB proarrhythmia can also be observed in patients with apparently
normal hearts, such as in the Brugada syndrome (BrS).3,11
Brugada syndrome is an inherited electrical disease associated with
sudden cardiac death (SCD) and characterized by ST-segment eleva-
tion and T-wave inversion in the right precordial electrocardiogram
(ECG) leads (Type I ECG).12 Brugada syndrome involves impaired
sodium-channel function, through loss of function mutations in the
underlying SCN5A gene and/or decreased expression mediated by
common genetic variants.13,14 Patients with suspected BrS often do
not manifest the diagnostic Type I ECG at baseline. An infusion of a
SCB, such as ajmaline, is performed in these cases to unmask the diag-
nostic Type I ECG. Although the prevalence of BrS has been trad-
itionally considered to be low, recent data show that the prevalence
of ajmaline-induced Type I BrS ECG is 5% in the general popula-
tion15 and up to 28% in families of SCD cases with normal
autopsy.16,17
As in drug-induced torsades de pointes, sporadic cases harbouring
rare pathogenic variants in SCN5A point to the genetic basis of proar-
rhythmia risk in the setting of SCB use.3,18 Such mutations may ex-
plain some cases of drug toxicity. Whether more common genetic
variants predict inter-individual variability in the cardiac electrical re-
sponse to sodium-channel blockade, akin to drug-induced QTc pro-
longation,2 remains entirely unexplored.
Recent genome-wide association studies (GWAS) of PR interval19
and QRS duration20 have identified multiple loci harbouring common
genetic variants that impact on these conduction ECG parameters.
A GWAS of BrS13 also identified three common single-nucleotide
polymorphisms (SNPs) associated with BrS with moderate effect
sizes. We now test the hypothesis that a weighted combination of
such common genetic variants predicts the individual response to so-
dium-channel blockade. In a large set of 1400 consecutive patients
who underwent ajmaline testing, we demonstrate that polygenic risk
scores (PRS) based on SNPs modulating QRS duration and risk of
BrS, are independent predictors of the response to sodium-channel
blockade. Findings from this proof of concept study establish a
framework for individualized risk prediction of SCB cardiac toxicity.
We also developed and internally validated a prediction model of
ajmaline-induced Type I BrS ECG that could be used in the diagnostic
strategy when suspecting BrS.
Methods
Patient inclusion and ajmaline testing
The study included 1400 consecutive consenting patients that underwent
ajmaline testing in the Amsterdam University Medical Centre, location
Academic Medical Center (AMC; Amsterdam) from December 2004 to
September 2016 for suspected BrS. Ajmaline testing was performed as
recently described17 in a reproducible manner by one physician (H.L.T.).
Intravenous ajmaline was administered at consecutive boluses of 10 mg/
min. A 10-s ECG was recorded 1 min after each bolus using a GE
Healthcare electrocardiograph. The test was stopped when the target
dose of 1 mg/kg rounded up to the next 10 mg was reached, if ventricular
arrhythmia occurred, or at the manifestation of a Type I BrS pattern,
defined as an ST elevation >2 mm with a coved morphology in any lead
among V1–V2 in the 2nd to 4th intercostal spaces.12
Electrocardiogram processing and dose–
response modelling
PR intervals and QRS durations of 26 721 ECGs recorded during ajmaline
testing of included individuals were measured with the Modular ECG
Analysis System (MEANS),21 an extensively evaluated computer pro-
gramme often used to analyse ECGs from large population datasets,
including recent GWAS.19,20 MEANS determines common waveform
markers (i.e. beginning of P-wave and QRS complex, and end of QRS) for
all 12 leads together on one representative averaged beat (see two exam-
ples in Figure 1A). Measurements corresponding to identical sample-dose
pairs were averaged and individuals with less than 4 PR or QRS data
points or with a baseline QRS >120 ms were removed. The presence of a
Type II or III BrS patterns at baseline was assessed by manually reviewing
the ECG of all participants recorded immediately prior to drug infusion
with V1 and V2 recorded at the 4th (normal) and 3rd (high) intercostal
spaces.
The relations of PR and QRS with weight-adjusted ajmaline dose (in
mg/kg) were fit to a linear mixed model using restricted maximum likeli-
hood, with fixed and random effects for both intercept and slope (Figure
1B). Individuals having poor dose–response fits (defined as having >_1 data
point with a residual absolute value greater than 3 standard deviations,
SDs) were identified and the waveform markers in all their ECGs were
manually checked and adjusted if necessary, with the assumption that
poor fit may reflect improper automated detection of complex
waveforms.
While inter-individual variability in baseline PR and QRS (i.e. intercept)
has been the subject of recent GWAS,19,20 the variability of the response
to sodium-channel blockade (i.e. slope) has not yet been explored
(Figure 1). In the present study, we sought to identify clinical and genetic
predictors of PR and QRS dose–response slopes (referred to as ‘PR
slope’ and ‘QRS slope’).
Genome-wide array genotyping, quality
control and imputation
We performed genome-wide array genotyping for all study subjects on
the Illumina Global Screening Array at the Genome analysis centre at
Helmholtz Zentrum Mu¨nchen. All downstream analyses were performed
at the AMC. Single-nucleotide polymorphism-level and sample-level
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..quality control (QC) was performed using PLINKv1.9 and in-house
scripts. We excluded ambiguous SNPs (A/T or C/G) and those with miss-
ingness >0.05, Hardy–Weinberg equilibrium test P< 10-6, minor allele
frequency (MAF) <0.001. Samples with missingness >0.03, inbreeding co-
efficient jFj>0.1, as well as those with sex mismatch were excluded.
Related samples were not excluded. Samples with divergent ancestry
were excluded from PRS analysis (see below).
Genome-wide imputation was performed using Eagle2 phasing,
Minimac3, and the Haplotype reference consortium (HRCr1.1) panel
implemented on the Michigan Imputation Server.22 After imputation,
only SNPs with MAF > 0.05 and a Minimac3 R2 > 0.5 were included.
PRS analyses
Association data from previously published GWAS on PR interval,19 QRS
duration,20 and BrS13 were used to calculate weighted (PRS) for PR
(PRSPR), QRS (PRSQRS), and BrS (PRSBrS), respectively. Each PRS was
calculated for each individual as the sum of [alternate allele dosage 
published regression coefficient (b) for that allele] for each independent
SNP reaching genome-wide significance in the published study
(Supplementary material online, Table S1): 44, 26, and 3 SNPs for PRSPR,
PRSQRS, and PRSBrS, respectively. Since the reported regression coeffi-
cients are primarily derived from European populations, we used geno-
typic principal component analysis to exclude non-European samples for
PRS analyses.
The association of PRS and clinical parameters with the PR and QRS
slopes was performed using univariable linear regression followed by
multivariable analysis, with only variables with a P< 0.05 in the univariable
analyses included in the model. A linear mixed effect model was used to
account for genetic relatedness using a kinship matrix (R lmekin function
in the coxme package). The genetic relatedness matrix was constructed
using GCTA.23 The association of PRS and clinical parameters with the
appearance of a Type I BrS ECG was performed using univariable and
multivariable logistic regression.
Development and validation of a Brugada
syndrome risk prediction model
The discriminative value of the PRSBrS with or without clinical variables in
predicting ajmaline-induced Type I BrS ECG was assessed using a
receiver-operating characteristic curve, C-statistic, and sensitivity, specifi-
city, and positive/negative predictive values at different thresholds, using
A
B C
Figure 1 Variability in ajmaline response and linear mixed modelling. (A) Electrocardiograms (leads V1 and V4) at baseline (top) and peak
ajmaline infusion (bottom) of two representative cases. Automatic waveform markers are overlaid on the electrocardiograms. Electrocardiogram
scale (0.5 mV/200 ms) on the left. (B) Schematic representation of linear mixed modelling of ajmaline dose–response on PR and QRS, illustrating
the fixed and random effects on intercept and slope, where fixed effects are average responses, while random effects are individual differences
from the average. (C) Automatic measurements (points) and linear mixed model fit (line) of QRS vs. weight-adjusted ajmaline dose for the two cases
shown in (A).
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the pROC package in R. Internal validation of the predictive model was
performed using bootstrapping by fitting the model to 1000 bootstrap
datasets of identical size as the study population, using the rms package.
Optimism-corrected C-statistic and R2 as well as calibration slope were
calculated.
As an alternative strategy to bootstrapping, we derived a prediction
model from patients that had ajmaline testing prior to 31 December
2011, and validated it in those that had the test in and following 2012.
General statistics
We systematically assessed normal distribution using the Shapiro–Wilk
test. Normally distributed variables are presented as mean ± standard de-
viation and compared using a Student’s t-test. Non-normally distributed
variables are presented as median (interquartile range) and compared
using the Wilcoxon rank-sum test. Categorical variables are presented as
N (%) and compared using the Pearson v2 test. The statistical significance
level was set to P< 5 10-8 for GWAS. The primary objectives were to
test the association of (i) PRSPR with PR slope, (ii) PRSQRS with QRS
slope, and (iii) PRSBrS with ajmaline-induced Type I pattern, corrected for
other associated variables. Significance threshold for these primary analy-
ses was set to P< 0.05/3 (0.017; Bonferroni correction) and P< 0.05 for
other secondary analyses and variable selection.
Results
Study population and sample quality
control
A total of 1400 individuals were included and underwent genome-
wide array genotyping. During QC, 32 were excluded (25 with high
genotype missingness and 7 with sex mismatch). Basic characteristics
of the remaining 1368 individuals are presented in Supplementary
material online, Table S2. Of these, 530 were singletons and 838
belonged to one of 249 families.
Electrocardiogram processing and dose–
response modelling
In total, 10 824 PR and 10 966 QRS data points (Supplementary ma-
terial online, Figure S1) were used for dose–response linear mixed
modelling. Supplementary material online, Figure S2 shows the resid-
uals vs. fitted values and measured vs. fitted values for PR and QRS in
this initial modelling. We manually inspected and readjusted ECG
waveform markers, as necessary, for individuals with any outlier data
point, as prespecified. Linear mixed modelling was again performed in
the corrected dataset. This resulted in an improved fit
(Supplementary material online, Figure S3), with a coefficient of deter-
mination (R2) of 0.83 for PR and 0.78 for QRS. The average baseline
PR was 162 ms (fixed effect intercept) and the average PR change
with ajmaline was 51 ms/mg/kg (fixed effect slope). The correspond-
ing values for QRS were 101 ms and 36 ms/mg/kg, respectively.
Intercepts and slopes showed large variability for both PR and QRS
(Supplementary material online, Figure S4).
Array genotyping analysis
After QC, 523 549 SNPs were retained and 4.1M common SNPs
were well imputed using the Haplotype Reference Consortium
panel. A single SNP genome-wide association analysis was performed
as described in the Supplementary material online, Data Supplement
and shown in Supplementary material online, Figures S5 and S6, Table
S3. The SCN5A–SCN10A locus (lead SNP rs10428132) was signifi-
cantly associated with ajmaline-induced Type I BrS ECG
(P= 8.6 10-19).
Of the 1368 samples passing QC, 111 were excluded from PRS-
based analyses because of non-European ancestry. The distributions
of PRS across the cohort are presented in Supplementary material
online, Figure S7.
Predictors of baseline PR and QRS
Baseline PR and QRS were significantly higher in SCN5A mutation car-
riers vs. non-carriers (PR: 194 ± 37 vs. 160± 25 ms, P= 3 10-9;
QRS: 114 ± 19 vs. 101 ± 13 ms, P= 4 10-6) and were positively cor-
related with PRSPR [correlation coefficient (r) = 0.23; P= 3 10-15]
and PRSQRS (r= 0.15; P= 6 10-7), respectively, in mutation non-
carriers (Figure 2A and B).
Predictors of PR slope
As for baseline PR, PR slope was also higher in SCN5A mutation car-
riers and was positively correlated with PRSPR (Figure 2C). We
assessed the association of the PR slope with clinical and genetic
parameters using a linear mixed model (Table 1). In univariable ana-
lysis, sex, PRSPR, baseline PR, and the presence of SCN5A pathogenic
variant were associated with PR slope. In multivariable analysis, sex
and baseline PR were significantly associated with PR slope, while the
association of PRSPR was not statistically significant (P= 0.062).
Because only30% of patients underwent SCN5A sequencing as per
clinical indications, the presence of a mutation was not integrated in
the predefined multivariable model (Table 1). Results from a multi-
variable model including SCN5A mutation status, when available, ap-
pear in Supplementary material online, Table S4. Considering the
correlation between PR and PRSPR, we assessed for collinearity in the
model by calculating the variance inflation factors. Variance inflation
factors were 1.09 and 1.05 for PR and PRSPR, respectively, suggesting
negligible collinearity.
When excluding patients known to have an SCN5A mutation, sex,
PRSPR, and baseline PR were all associated with PR slope. When also
excluding patients with a Type I BrS ECG, only sex and baseline PR
remained significantly associated with PR slope (Table 1).
Predictors of QRS slope
QRS slope was higher in SCN5A mutation carriers and was positively
correlated with PRSQRS (Figure 2). The results of linear mixed model-
ling of QRS slope are shown in Table 2. In univariable analysis, age,
PRSQRS, and the presence of an SCN5A pathogenic variant were asso-
ciated with the QRS slope. In multivariable analysis combining age
and PRSQRS, both variables were independently and significantly asso-
ciated with QRS slope. Both age and PRSQRS remained independently
associated with QRS slope in the subgroup of patients without a
pathogenic SCN5A variant, as well as those without a BrS Type I ECG
(Table 2). Results from a multivariable model including SCN5A muta-
tion status appear in Supplementary material online, Table S4. The as-
sociation of PRSQRS with QRS slope was not significant when SCN5A
mutation status was included in the model. This may reflect lower
statistical power (sample size 295 vs. 1097) but also a higher propor-
tion of SCN5A carriers in whom the effect of common variants is
3100 R. Tadros et al.
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fect P= 0.004).
Predictors of Type I Brugada syndrome
electrocardiogram and ventricular
arrhythmia
The results of univariable and multivariable logistic regression for the
development of a Type I BrS ECG are shown in Table 3. The 3-SNP
PRSBrS was strongly associated with ajmaline-induced Type I BrS
ECG. Baseline QRS, presence of a Type II or III pattern on baseline
ECG, and family history of BrS were also independent predictors of
the BrS Type I ECG, both in the overall cohort and when excluding
SCN5A mutation carriers. PRSQRS and PRSPR were associated with a
Type I ECG in univariable but not multivariable analyses, likely be-
cause of their strong correlation with PRSBrS (r= 0.49 for PRSPR and
0.28 for PRSQRS; P< 10
-15 for both) reflecting the important contri-
bution of the SCN5A–SCN10A locus in all three PRS (see
Supplementary material online, Table S1). Figure 3A represents the
number of individuals with and without an ajmaline-induced Type I
A B
C D
Figure 2 Correlation plots of baseline PR and QRS vs. PRSPR (A) and PRSQRS (B), respectively and PR and QRS slopes vs. PRSPR (C) and PRSQRS
(D), respectively. Red and blue markers represent SCN5A mutation carriers and those without a known SCN5A mutation, respectively. The line repre-
sents the linear regression between correlated variables in cases without a known SCN5A mutation, with the correlation coefficient (r) and Pearson’s
correlation test P-value (P) on the top left corner. Legend applies to all panels. Arrows in panels B and D highlight the two cases shown in Figure 1.
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Table 1 Regression analysis for PR slope in patients of European ancestry
Variables All individuals
No SCN5A mutation
No SCN5A mutation and
no Type I BrS ECGUnivariable Multivariable
b (SE) P-value b (SE) P-value b (SE) P-value b (SE) P-value
Sex (female) 2.5 (0.9) 4.0 10-3 3.1 (0.9) 2.3 10-4 3.1 (0.9) 2.5 10-4 3.0 (1.0) 2.7 10-3
Age (years) -0.02 (0.03) 0.41 NA NA NA NA NA NA
PRSPR 0.22 (0.08) 3.4 10-3 0.14 (0.08) 6.2 10-2 0.16 (0.08) 3.5 10-2 0.18 (0.09) 5.1 10-2
Baseline PR (ms) 0.08 (0.02) 2.7 10-6 0.08 (0.02) 1.7 10-6 0.07 (0.02) 1.3 10-4 0.07 (0.02) 3.3 10-4
SCN5A mutation 7.9 (2.5) 1.7 10-3 NA NA NA NA NA NA
SCN5A mutation status is not included in the multivariable models because of high missing data related to the fact that SCN5A sequencing was clinically-driven. Only multivari-
able analysis results are shown for the subgroups ‘no SCN5A mutation’ and ‘no SCN5A mutation and no Type I BrS’.
b, regression coefficient; NA, not applicable; SE, standard error of the b.
............................................................................
....................................... ................................................................................ .................................
....................................................................................................................................................................................................................
Table 2 Regression analysis for QRS slope in patients of European ancestry
Variables All individuals
No SCN5A mutation
No SCN5A mutation and
no Type I BrS ECGUnivariable Multivariable
b (SE) P-value b (SE) P-value b (SE) P-value b (SE) P-value
Sex (female) 0.69 (0.72) 0.34 NA NA NA NA NA NA
Age (years) 0.12 (0.02) 3.9 10-7 0.12 (0.02) 3.2 10-7 0.10 (0.02) 2.2 10-6 0.09 (0.02) 1.8 10-4
PRSQRS 0.80 (0.22) 3.0 10-4 0.80 (0.22) 2.5 10-4 0.93 (0.20) 2.5 10-6 0.58 (0.21) 6.5 10-3
Baseline QRS (ms) 0.05 (0.04) 0.13 NA NA NA NA NA NA
SCN5A mutation 21.3 (2.2) 1.6 10-18 NA NA NA NA NA NA
SCN5A mutation status is not included in the multivariable models because of high missing data related to the fact that SCN5A sequencing was clinically-driven. Only multivari-
able analysis results are shown for the subgroups ‘no SCN5A mutation’ and ‘no SCN5A mutation and no Type I BrS’.
b, regression coefficient; NA, not applicable; SE, standard error of the b.
.....................................................................................................
............................................................................................... ...............................................
....................................................................................................................................................................................................................
Table 3 Regression analysis for an ajmaline-induced Type I BrS ECG in patients of European ancestry
Variables All individuals
No SCN5A mutationUnivariable Multivariable
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Sex (female) 1.014 (0.963–1.067) 0.58 NA NA NA NA
Age (per 10-year increase) 1.018 (1.001–1.036) 4.8 10-2 1.005 (0.988–1.023) 0.57 NA NA
PRSPR 1.017 (1.013–1.022) 3.6 10-13 1.002 (0.997–1.007) 0.42 NA NA
Baseline PR (per 10-ms increase) 1.015 (1.005–1.026) 3.4 10-3 1.005 (0.995–1.016) 0.33 NA NA
PRSQRS 1.047 (1.031–1.063) 9.3 10-9 1.012 (0.995–1.028) 0.16 NA NA
Baseline QRS (per 10-ms increase) 1.062 (1.035–1.090) 7.7 10-6 1.032 (1.006–1.059) 1.6 10-2 1.003 (1.000–1.005) 4.3 10-2
PRSBrS 1.174 (1.138–1.210) 3.0 10-24 1.141 (1.101–1.183) 1.3 10-12 1.159 (1.124–1.195) 4.1 10-20
Baseline Type II or III pattern 1.388 (1.289–1.494) 1.2 10-17 1.270 (1.172–1.376) 6.3 10-9 1.296 (1.197–1.403) 2.6 10-10
FHx BrS 1.116 (1.061–1.175) 4.8 10-5 1.113 (1.058–1.171) 3.4 10-5 1.100 (1.046–1.157) 2.3 10-4
SCN5A mutation 1.221 (1.064–1.402) 4.3 10-3 NA NA NA NA
SCN5A mutation status is not included in the multivariable models because of high missing data related to the fact that SCN5A sequencing was clinically-driven. Only multivari-
able analysis results are shown for the subgroup ‘no SCN5A mutation’.
FHx BrS, family history of BrS; NA, not applicable; OR (95% CI), odds ratio and 95% confidence interval.
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..BrS ECG per PRSBrS quintile. As for PR and QRS slopes, results from
a multivariable model including SCN5A mutation status, when avail-
able, appear in Supplementary material online, Table S4. Of note, in a
bivariable interaction model including both SCN5A mutation status
and PRSBrS, both variables were independently associated with Type I
BrS ECG with a significant interaction effect (P= 0.049), where the
BrS risk increasing effect of PRSBrS was non-significant in SCN5A mu-
tation carriers.
Ajmaline infusion was associated with the appearance of ventricu-
lar ectopy in 4% of patients. The presence of ajmaline-induced
ventricular arrhythmias was significantly associated with the presence
of an SCN5A pathogenic variant (P= 0.003). Furthermore, in the pri-
mary analysis of patients with European ancestry, those with induced
ventricular arrhythmias tended to have a higher PRSBrS than those
without arrhythmias (-0.1± 0.7 vs. -0.31 ± 0.8; P= 0.056). In a subse-
quent (non-predefined) analysis where we also included cases of
East-Asian ancestry, who have similar effect sizes in the BrS GWAS,13
the association became significant (P= 0.049).
The weight-adjusted dose of ajmaline required to induce a Type I
BrS ECG was significantly lower in SCN5A mutation carriers
B
A
Figure 3 (A) Bar plot representing number of individuals per PRSBrS quintile in the cohort without a known SCN5A mutation, with (red bars) and
without (blue bars) ajmaline-induced Type I Brugada syndrome electrocardiogram. (B) Correlation plot of ajmaline dose required to induce a Type I
Brugada syndrome electrocardiogram and PRSBrS for SCN5A mutation carriers (red markers) and non-carriers (blue markers). Line represents the
linear regression in cases without a known SCN5A mutation, with the correlation coefficient (r) and test P-value (P) at the top left corner.
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(0.76± 0.28 mg/kg) than in the others (0.97 ± 0.25 mg/kg, P< 10-5). In
non-mutation carriers, the PRSBrS was negatively correlated with the
weight-adjusted dose of ajmaline required to induce a Type I ECG
(r= -0.14; P= 0.01; Figure 3B). This suggests an allelic dose-response
where the higher number of BrS associated alleles an individual car-
ries, the more sensitive he is to sodium-channel blockade.
Development and validation of a drug-
induced Brugada syndrome risk predic-
tion model
We assessed the predictive value of PRS in ajmaline-induced BrS.
Using PRSBrS as a sole predictor (Supplementary material online,
Figure S8A), the C-statistic was 0.68 [95% confidence interval (CI)
0.65–0.71]. Using the Youden’s index, the optimal PRSBrS threshold
for predicting an ajmaline-induced Type I BrS ECG was -0.02, corre-
sponding to 64% sensitivity and specificity. Test performance using
other PRSBrS thresholds and percentiles is shown in Table 4. A PRSBrS
threshold at the 90th percentile (þ0.91) had 95% specificity for an
ajmaline-induced BrS, while a threshold at the 10th percentile (-1.41)
provided a sensitivity of 99% to exclude BrS, potentially alleviating
the need to perform ajmaline testing in this population, representing
10% of the studied cohort.
Adding family history of BrS, baseline QRS duration and Type II or
III ECG to PRSBrS resulted in a significantly better prediction model
[C-statistic 0.741 (95% CI 0.710–0.773); R2 0.197; likelihood ratio test
....................................................................................................................................................................................................................
Table 4 PRSBrS diagnostic performance for predicting BrS at different thresholds and at optimal Youden’s index
PRSBrS threshold (percentile) 21.4 (10th) 20.9 (30th) 20.4 (50th) 20.02 (Youden) 0.1 (70th) 0.9 (90th)
Specificity 0.06 0.36 0.57 0.64 0.76 0.95
Sensitivity 0.99 0.85 0.70 0.64 0.49 0.12
Negative predictive value 0.93 0.84 0.81 0.81 0.77 0.71
Positive predictive value 0.32 0.37 0.41 0.42 0.47 0.53
Figure 4 Probability estimate of ajmaline-induced Type I Brugada syndrome electrocardiogram in patients with suspected Brugada syndrome, de-
pending on QRS duration and presence of Type II or III Brugada syndrome electrocardiogram at baseline, family history of Brugada syndrome, as well
as PRSBrS. Shaded area represent the 95% confidence interval. PRSBrS = 0.55#rs11708996_C - 0.94#rs10428132_Gþ 0.46#rs9388451_C,
where #rs11708996_C, #rs10428132_G, and #rs9388451_C indicate the number of respective alleles an individual carries.
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..P< 10-5; Supplementary material online, Figure S8B]. Validation of the
four-variable model using bootstrapping suggests minimal optimism/
overfitting: the optimism-corrected C-statistic is 0.737 and R2 is 0.188
with a calibration slope of 0.98. As an alternative to bootstrapping,
we also derived a prediction model in cases tested prior to 2012
(N= 380) and validated it in those tested in and after 2012. Model
performance was good, with a C-statistic 0.732, R2 0.09 and calibra-
tion slope 0.86.
To facilitate clinical implementation, Figure 4 provides the probabil-
ity estimates of drug-induced BrS based on the validated four-variable
prediction model. PRSBrS can be calculated following genotyping of
three SNPs (equation in legend of Figure 4).
Discussion
Drugs with cardiac sodium-channel blocking properties such as
Class I antiarrhythmic drugs, anti-epileptics, and tricyclic anti-
depressants have been associated with major cardiac adverse
events in diverse populations.3–10 Prediction of response could re-
sult in increased use of effective drugs in lower risk patients,
while decreasing adverse events through better surveillance and
withdrawal in high-risk patients. The standard ECG is used to
monitor SCB toxicity by examining conduction parameters, mainly
the QRS duration. Cardiovascular societies recommend withdraw-
al of Class I anti-arrhythmic drugs in the presence of QRS pro-
longation exceeding >_25% of the baseline value24 and avoidance
of all SCBs in patients with the Type I BrS ECG, either spontan-
eously or drug-induced.12
The genetic determinants of PR, QRS, and QT intervals have been
extensively studied through large-scale GWAS in the general popula-
tion.1,19,20 Single-nucleotide polymorphisms associated with QT in
the general population are also associated with drug-induced QT
prolongation.2,25 In contrast to drug-induced QT prolongation, the
genetic determinants of cardiac response to sodium-channel block-
ade have not yet been studied. The present study is, to the best of
our knowledge, the first to address this question.
Summary of study findings
Novel findings can be summarized as follows: (i) ajmaline-induced PR
and QRS changes accurately fit a linear model (Supplementary mater-
ial online, Figure S3); (ii) PRS combining 44 common variants associ-
ated with PR in the general population19 (PRSPR) is associated with
ajmaline-induced PR prolongation in addition to but not independently
of baseline PR and female sex (Table 1 and Figure 2C); (iii) PRS combin-
ing 26 common variants associated with QRS in the general popula-
tion20 (PRSQRS) as well as age are independently associated with
ajmaline-induced QRS prolongation (Table 2 and Figure 2D); (iv) fam-
ily history of BrS, baseline QRS, presence of a Type II or III BrS at
baseline ECG, and a 3-SNP PRS derived from a case–control BrS
GWAS13 (PRSBrS) are independently associated with ajmaline-
induced Type I BrS ECG (Table 3 and Figure 3A); (v) a prediction
model integrating PRSBrS, baseline ECG, and family history of BrS
Take home ﬁgure Figure summarizing the proof of concept that polygenic scores may be used to predict response to sodium-channel blockers
in the context of suspected Brugada syndrome and conduction slowing.
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performs well to predict the occurrence of ajmaline-induced Type I
ECG (Figure 4, Table 4 and Supplementary material online, Figure S8).
Mechanistic insights: central role of
SCN5A in sodium-channel blockade
response
SCN5A codes for the a-subunit of the cardiac sodium-channel
Nav1.5, the target of Class I antiarrhythmic drugs such as ajmaline.
Nav1.5 is also blocked through non-specific binding by drugs directed
to other pharmacologic targets.3,26 Rare coding variants in SCN5A that
alter the amino acid sequence can result in impaired Nav1.5 function
or decreased membrane expression, resulting in higher sensitivity to
sodium-channel blockade.3,18,27 Common non-coding variants in the
SCN5A–SCN10A locus are unequivocally associated with BrS as well
as electrocardiographic traits in the general population
(Supplementary material online, Table S1). These variants map to
gene regulatory elements and modify cardiac electrophysiology by
affecting expression of SCN5A.14 In the present study, we now show
that these same variants not only affect the resting ECG but also car-
diac electrical response to sodium-channel blockade (Supplementary
material online, Figure S5 and Table S3). Although a polygenic score
only including the SCN5A–SCN10A locus also predicts QRS slope and
BrS, SNPs in other loci have an added predictive value (data not
shown), suggesting that other loci also affect sodium-blocker sensitiv-
ity, perhaps in part by modulating transcription factors (e.g. TBX5,
HEY2).
Limitations
The study subjects were not randomly selected from the general
population but had ajmaline infusion for suspected BrS. This co-
hort was used because of large sample size, availability of raw
ECG data and DNA, as well as consistency in drug infusion per-
formed by an experienced physician. Validation of the findings in
a general population cohort using other SCBs is desirable. The
reproducibility of our QRS slope association results in the sub-
group of patients with neither an SCN5A mutation nor a Type I
BrS ECG is reassuring regarding applicability of the findings to
the general population.
In contrast to drug-induced QT prolongation,2 the proportion of
explained variability in ajmaline-induced PR and QRS slopes is low
(Figure 2C and D). Although this may reflect differences in the genetic
component of drug-induced QT prolongation vs. conduction slow-
ing, it may also reflect inter-individual pharmacokinetic variability (e.g.
distribution volumes) that are not accounted for in the present study.
Although not logistically possible, if drug concentrations were used
instead of infused drug dose, PRS may have possibly explained a
larger portion of the variability. The statistically robust associations
provide a strong proof of concept on which to base future pharma-
cogenomic studies.
Sequencing of SCN5A was performed as clinically relevant (mostly
because a Type I BrS ECG occurred during ajmaline testing). As such,
SCN5A mutation status was known for less than a third of the study
population. Extrapolation of PRS associations to the subgroup of
patients with SCN5A mutations should be made with caution (see
Supplementary material online, Table S4). Patients with SCN5A
mutations are sensitive to sodium-channel blockade regardless of
their polygenic risk.
Potential clinical applications
The current findings may translate into clinical applications in two set-
tings. First, SNP genotyping may be performed to assess pre-test
probability when considering drug testing in suspected BrS (Figure 4).
A BrS diagnostic algorithm integrating SNP genotyping could have
several potential advantages compared with current practice: (i)
Reduction of test-related adverse events, such as life-threatening ar-
rhythmia (2% in Conte et al.28) and ajmaline-induced cholestatic
liver injury;29–31 (ii) Reduction of cost considering the higher
expenses of SCB testing (performed in a hospital setting) compared
with SNP genotyping; and (iii) Identification of family members at risk
of BrS in centres with limited access to drug testing or no access to
ajmaline (other drugs have limited sensitivity32,33). Prospective stud-
ies are needed to assess the predictive values and cost-effectiveness
in a real-world setting. It is worth mentioning that sensitivity and spe-
cificity of PRSBrS are within the same range as those of some com-
monly used diagnostic tests, such as exercise electrocardiography to
diagnose coronary artery disease.
A second potential application of study findings is pre-emptive gen-
otyping prior to prescription of drugs with cardiac sodium-channel
blocking activity. PRS may be used to identify patients at risk of drug
toxicity. Although high PRSQRS and PRSBrS may not be sufficiently
predictive of adverse events to contraindicate those drugs upstream,
it may justify closer patient follow-up using electrocardiography, with
drug withdrawal in patients who show evidence of toxicity. The cur-
rent effect sizes for PRSPR and PRSQRS are modest and it is expected
that further understanding of the genetic determinants of response
to sodium-channel blockade would improve risk assessment.
Conclusions
PRS are associated with ajmaline-induced cardiac conduction slowing
and BrS. The current study provides a strong proof-of-concept in
support of an innovative strategy using genotyping of common SNPs
in the diagnostic strategy for BrS and possibly in predicting SCB
toxicity.
Supplementary material
Supplementary material is available at European Heart Journal online.
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